Demographics, treatment trends, and survival rate in incident pulmonary artery hypertension in Korea: A nationwide study based on the health insurance review and assessment service database

Shinjeong Song, Sang Eun Lee, Sang Kwon Oh, Seong A. Jeon, Ji Min Sung, Jae Hyeong Park, Hyuk Jae Chang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Epidemiologic data regarding pulmonary arterial hypertension (PAH) have relied on registries from Western countries. We assessed the current status of PAH in the Korean population. The Health Insurance Review and Assessment Service (HIRA) claim database, which comprises nationwide medical insurance data of Koreans from 2008–2016, was assessed to determine the current status of PAH. Overall, 1,307 patients were newly diagnosed with PAH from 2008–2016 (0.0005%, annual incidence: 4.84 patients/1 million people/year). The mean age at diagnosis was 44±13 years (range 18–65) and patients were mostly women (n = 906, 69.3%). Cases of idiopathic PAH (51.6%) accounted for the largest proportion, followed by acquired PAH (APAH) associated with congenital heart disease (25.8%) and APAH with connective tissue disease (17.2%). Overall, 807 (61.7%) patients received a single PAH-specific treatment based on their last prescription, of which bosentan (50.6%) was the most frequently used. Only 240 (18.4%) patients received combination therapy, with the bosentan-beraprost combination (32.9%) being the most common. During the mean followup of 1.9 years, the 1-, 2-, 3-, and 5-year estimated survival rates were 85%, 62%, 54%, and 46%, respectively. The prevalence and incidence of PAH in the Korean population is currently comparable with that in previous registries. The 5-year survival rate was slightly higher in the Korean population than previously reported.

Original languageEnglish
Article numbere0209148
JournalPloS one
Volume13
Issue number12
DOIs
Publication statusPublished - 2018 Dec

Fingerprint

Health insurance
health insurance
beraprost
national surveys
pulmonary artery
Health Insurance
Korea
Pulmonary Hypertension
Pulmonary Artery
hypertension
Korean Peninsula
demographic statistics
Survival Rate
survival rate
lungs
Demography
Databases
Insurance
Polycyclic aromatic hydrocarbons
Tissue

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

@article{d83871aea5834705a37c45b4590a1632,
title = "Demographics, treatment trends, and survival rate in incident pulmonary artery hypertension in Korea: A nationwide study based on the health insurance review and assessment service database",
abstract = "Epidemiologic data regarding pulmonary arterial hypertension (PAH) have relied on registries from Western countries. We assessed the current status of PAH in the Korean population. The Health Insurance Review and Assessment Service (HIRA) claim database, which comprises nationwide medical insurance data of Koreans from 2008–2016, was assessed to determine the current status of PAH. Overall, 1,307 patients were newly diagnosed with PAH from 2008–2016 (0.0005{\%}, annual incidence: 4.84 patients/1 million people/year). The mean age at diagnosis was 44±13 years (range 18–65) and patients were mostly women (n = 906, 69.3{\%}). Cases of idiopathic PAH (51.6{\%}) accounted for the largest proportion, followed by acquired PAH (APAH) associated with congenital heart disease (25.8{\%}) and APAH with connective tissue disease (17.2{\%}). Overall, 807 (61.7{\%}) patients received a single PAH-specific treatment based on their last prescription, of which bosentan (50.6{\%}) was the most frequently used. Only 240 (18.4{\%}) patients received combination therapy, with the bosentan-beraprost combination (32.9{\%}) being the most common. During the mean followup of 1.9 years, the 1-, 2-, 3-, and 5-year estimated survival rates were 85{\%}, 62{\%}, 54{\%}, and 46{\%}, respectively. The prevalence and incidence of PAH in the Korean population is currently comparable with that in previous registries. The 5-year survival rate was slightly higher in the Korean population than previously reported.",
author = "Shinjeong Song and Lee, {Sang Eun} and Oh, {Sang Kwon} and Jeon, {Seong A.} and Sung, {Ji Min} and Park, {Jae Hyeong} and Chang, {Hyuk Jae}",
year = "2018",
month = "12",
doi = "10.1371/journal.pone.0209148",
language = "English",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

Demographics, treatment trends, and survival rate in incident pulmonary artery hypertension in Korea : A nationwide study based on the health insurance review and assessment service database. / Song, Shinjeong; Lee, Sang Eun; Oh, Sang Kwon; Jeon, Seong A.; Sung, Ji Min; Park, Jae Hyeong; Chang, Hyuk Jae.

In: PloS one, Vol. 13, No. 12, e0209148, 12.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Demographics, treatment trends, and survival rate in incident pulmonary artery hypertension in Korea

T2 - A nationwide study based on the health insurance review and assessment service database

AU - Song, Shinjeong

AU - Lee, Sang Eun

AU - Oh, Sang Kwon

AU - Jeon, Seong A.

AU - Sung, Ji Min

AU - Park, Jae Hyeong

AU - Chang, Hyuk Jae

PY - 2018/12

Y1 - 2018/12

N2 - Epidemiologic data regarding pulmonary arterial hypertension (PAH) have relied on registries from Western countries. We assessed the current status of PAH in the Korean population. The Health Insurance Review and Assessment Service (HIRA) claim database, which comprises nationwide medical insurance data of Koreans from 2008–2016, was assessed to determine the current status of PAH. Overall, 1,307 patients were newly diagnosed with PAH from 2008–2016 (0.0005%, annual incidence: 4.84 patients/1 million people/year). The mean age at diagnosis was 44±13 years (range 18–65) and patients were mostly women (n = 906, 69.3%). Cases of idiopathic PAH (51.6%) accounted for the largest proportion, followed by acquired PAH (APAH) associated with congenital heart disease (25.8%) and APAH with connective tissue disease (17.2%). Overall, 807 (61.7%) patients received a single PAH-specific treatment based on their last prescription, of which bosentan (50.6%) was the most frequently used. Only 240 (18.4%) patients received combination therapy, with the bosentan-beraprost combination (32.9%) being the most common. During the mean followup of 1.9 years, the 1-, 2-, 3-, and 5-year estimated survival rates were 85%, 62%, 54%, and 46%, respectively. The prevalence and incidence of PAH in the Korean population is currently comparable with that in previous registries. The 5-year survival rate was slightly higher in the Korean population than previously reported.

AB - Epidemiologic data regarding pulmonary arterial hypertension (PAH) have relied on registries from Western countries. We assessed the current status of PAH in the Korean population. The Health Insurance Review and Assessment Service (HIRA) claim database, which comprises nationwide medical insurance data of Koreans from 2008–2016, was assessed to determine the current status of PAH. Overall, 1,307 patients were newly diagnosed with PAH from 2008–2016 (0.0005%, annual incidence: 4.84 patients/1 million people/year). The mean age at diagnosis was 44±13 years (range 18–65) and patients were mostly women (n = 906, 69.3%). Cases of idiopathic PAH (51.6%) accounted for the largest proportion, followed by acquired PAH (APAH) associated with congenital heart disease (25.8%) and APAH with connective tissue disease (17.2%). Overall, 807 (61.7%) patients received a single PAH-specific treatment based on their last prescription, of which bosentan (50.6%) was the most frequently used. Only 240 (18.4%) patients received combination therapy, with the bosentan-beraprost combination (32.9%) being the most common. During the mean followup of 1.9 years, the 1-, 2-, 3-, and 5-year estimated survival rates were 85%, 62%, 54%, and 46%, respectively. The prevalence and incidence of PAH in the Korean population is currently comparable with that in previous registries. The 5-year survival rate was slightly higher in the Korean population than previously reported.

UR - http://www.scopus.com/inward/record.url?scp=85058861303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058861303&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0209148

DO - 10.1371/journal.pone.0209148

M3 - Article

C2 - 30566510

AN - SCOPUS:85058861303

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e0209148

ER -